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Abstract
Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens for diffuse
large B-cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, many
patients develop refractory or recurrent DLBCL and then receive autologous hematopoietic stem
cell transplantation (AuHCT). It is unclear to what extent pre-transplant exposure to rituximab
affects outcomes following AuHCT. Outcomes of 994 patients receiving AuHCT for DLBCL
between 1996 and 2003 were analyzed according to whether rituximab was (n=176, “+R” group)
or was not (n=818, “ −R” group) administered with front-line or salvage therapy prior to AuHCT.
The +R group had superior progression-free survival (50% versus 38%, p=0.008) and overall
survival (57% versus 45%, p=0.006) at 3 years. Platelet and neutrophil engraftment were not
affected by exposure to rituximab. Non-relapse mortality (NRM) did not differ significantly
between the +R and −R groups. In multivariate analysis, the +R group had improved progression-
free survival (relative risk of relapse/progression or death 0.64, p<0.001) and improved overall
survival (relative risk of death of 0.74, p=0.039). We conclude that pre-transplant rituximab is
associated with a lower rate of progression and improved survival following AuHCT for DLBCL,
with no evidence of impaired engraftment or increased NRM.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin
lymphoma (NHL). The probability of being cured by the initial treatment is predicted by the
International Prognostic Index (IPI), which accounts for age, performance status, tumor
stage, lactate dehydrogenase level (LDH) and the number of sites of extranodal disease as
prognostic variables.(1) Prior to the introduction of rituximab, the probability of long-term
survival ranged between 26 and 73%, depending on the IPI.(1) With the addition of
rituximab to standard frontline chemotherapy, outcomes have improved across all IPI
groups.(2–5)
For patients with relapsed, chemosensitive DLBCL, the Parma trial established high-dose
chemotherapy and AuHCT as superior to conventional salvage chemotherapy alone.(6)
However, this study was carried out in the pre-rituximab era, making its relevance in
DLBCL patients treated with rituximab-containing frontline or salvage regimens uncertain.
It has been reported that pre-transplant rituximab exposure may affect outcomes following
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high-dose therapy and AuHCT. For example, in one single-center retrospective study,
inclusion of rituximab in pre-transplant salvage therapy was associated with improved
survival and delayed platelet engraftment, in patients with intermediate-grade B-cell non-
Hodgkin lymphoma undergoing AuHCT.(7)
We hypothesized that pre-transplant exposure to rituximab may affect outcomes following
AuHCT for DLBCL, including relapse/progression, survival, toxicity, and engraftment.
Utilizing the Center for International Blood and Transplantation (CIBMTR) database, we
retrospectively compared outcomes for adult patients undergoing autotransplant for large
cell lymphoma, in rituximab naïve (−R) and rituximab exposed (+R) patients.
PATIENTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry
(IBMTR), Autologous Blood and Marrow Transplant Registry (ABMTR) and the National
Marrow Donor Program (NMDP) that comprises a voluntary working group of more than
450 transplant centers worldwide that contribute detailed data on consecutive allogeneic and
autologous transplants to a Statistical Center at the Health Policy Institute of the Medical
College of Wisconsin in Milwaukee or the NMDP Coordinating Center in Minneapolis.
Participating centers are required to report all consecutive transplants; compliance is
monitored by on-site audits. Subjects are followed longitudinally, with yearly follow-up.
Computerized checks for errors, physicians’ review of submitted data and on-site audits of
participating centers ensure data quality. Observational studies conducted by the CIBMTR
are done with a waiver of informed consent and in compliance with HIPAA regulations as
determined by the Institutional Review Board and the Privacy Officer of the Medical
College of Wisconsin.
The CIBMTR collects data at two levels: registration and research. Registration data include
disease type, age, sex, pretransplant disease stage and chemotherapy-responsiveness, date of
diagnosis, graft type (bone marrow- and/or blood-derived stem cells), high-dose
conditioning regimen, post-transplant disease progression and survival, development of a
new malignancy and cause of death. Requests for data on progression or death for registered
patients are at six-month intervals. All CIBMTR teams contribute Registration data.
Research data are collected on a subset of registered patients selected using a weighted
randomization scheme and include detailed disease, and pre- and post-transplant clinical
information.
Patients
A total of 1155 patients who underwent autologous transplantation for DLBCL between
1996 and 2003 were reported to the CIBMTR database. Eight patients with age at transplant
<18 years and 11 patients with post-transplant rituximab for maintenance were excluded.
Seventy-four patients who relapsed >10 years after initial diagnosis and 56 patients with
bone marrow grafts were excluded. Twelve patients who received rituximab with the
conditioning regimen were also excluded. A total of 994 patients were then analyzed. 176
received rituximab prior to transplant, either during first-line therapy and/or during salvage
therapy, while 818 patients were rituximab naïve at the time of transplant.
Study Endpoints
Outcomes analyzed included engraftment, non-relapse mortality (NRM), relapse/
progression, progression-free survival (PFS) and overall survival (OS). NRM was defined as
death within 28 days post-transplant or death without lymphoma progression. Subjects with
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lymphoma progression were censored at the time of progression and a cumulative incidence
estimate was derived with progression or relapse as the competing risk. Progression/relapse
was defined as progressive lymphoma post-transplant (≥28 d) or lymphoma recurrence. It
could follow a period of “stable” disease post-transplant, or a partial or complete remission.
Progression/relapse represents new or larger areas of lymphoma (≥25% increase in largest
diameter) compared to the best post-transplant lymphoma state. Relapse/progression was
summarized by the cumulative incidence estimate with NRM as the competing risk. For
PFS, subjects were considered treatment-failures at the time of lymphoma progression or
death from any cause. Subjects alive without evidence of lymphoma-progression were
censored at last follow-up and the PFS event was summarized by a survival curve. The OS
interval variable was defined as time from the date of transplant to the date of death or last
contact and summarized by a survival curve.
Statistical Analysis
Subject-, disease-, and transplant-related variables for subjects receiving rituximab and no
rituximab were compared using the chi-square statistic for categorical variables and the
Kruskal-Wallis test for continuous variables. Univariate probabilities of neutrophil and
platelet recovery and NRM were calculated using cumulative incidence curves to
accommodate corresponding competing risks.(8) Probabilities of OS and PFS were
calculated using Kaplan-Meier estimator.(9) Confidence intervals (CI) were calculated with
a log-transformation.
To compare the outcomes of NRM, progression/relapse, PFS and OS, a Cox proportional
hazards model was used to adjust for potential imbalance in baseline characteristics between
treatment cohorts. A stepwise forward method was used to identify covariates which
influenced outcomes. Each model contained the main effect (rituximab vs no rituximab).
Any covariate with a p-value ≤0.05 was considered significant. The proportionality
assumption for Cox-regression was tested by adding a time-dependent covariate for each
risk factor and each outcome. Tests indicated that all variables met the proportional-hazards
assumption except Karnofsky performance score. Cox regression models stratified on
Karnofsky score were used for each outcome event. Final results were expressed as relative
risks (RR) of the event and its 95% confidence intervals. The following variables were
considered in model building: rituximab vs. no rituximab (main effect), age at transplant,
Karnofsky performance status at transplant, number of lines of chemotherapy, bone marrow
involvement at transplant, disease status at transplant, size of largest lymphoma mass prior
to transplant, time from diagnosis to transplant, conditioning regimen, year of transplant and
G-CSF or GM-CSF given within 7-days post transplant. Rituximab vs. no rituximab was
retained in all steps of model-building since it was the main effect of interest. Potential
interactions between the main effect and all significant risk factors were tested, with no
interactions were detected for all significant risk factors. Analyses were performed using
SAS software, version 8.2 (SAS Institute).
RESULTS
Patient characteristics
Patient, disease and transplant related characteristics are summarized in Table 1. One
hundred seventy-six patients (+R cohort) received rituximab prior to transplant, either
during first-line therapy and/or during salvage therapy, and 818 patients (−R cohort) were
rituximab naïve at the time of transplant. The median follow-up of survivors was 44 months
and 62 months respectively for the +R and −R cohorts. Completeness of follow up was
90%.
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The +R group had a higher median age (58 vs. 52 years old, p<0.001) and a higher
proportion of patients aged 55 or older (55% vs. 40%, p<0.001). The +R group was also
more heavily pre-treated prior to transplant, with a higher proportion of patients having
received greater than 2 lines of chemotherapy (57% vs. 40%, p<0.001). However, this latter
difference may be accounted to some extent by the fact that rituximab alone was counted as
a regimen. Rituximab was administered with first-line chemotherapy in 38% of patients, and
with salvage therapy only in 62% of patients, with no patients receiving rituximab with both
first-line and salvage therapy. The cohorts were well matched for disease status at transplant,
bulky disease, second line age adjusted IPI scores and bone marrow involvement. In
addition, pre-transplant chemosensitivity and Ann Arbor stage at transplant did not differ
between the groups.
The +R and the −R groups received AuHCT at a similar interval from diagnosis and
received similar conditioning regimens. As expected, transplant occurred between 1999–
2003 in 96% of patients in the +R group, and between 1996–2001 in 93% of the −R patients
(p<0.001). A similar proportion of patients in each group received myeloid growth factors
post-transplant. Use of post-transplant radiation therapy was similar in the two groups.
Outcomes
Engraftment—The cumulative incidence of platelet and neutrophil engraftment at 28 and
100 days was similar in the two groups (Figure 1). There was no clinically significant
difference in the rates of neutrophil engraftment (defined as ANC>0.5 × 109/L) or platelet
engraftment (defined as a platelet count of 20,000/µL with no transfusion requirement)
between the 2 cohorts. The patients who received rituximab within 3 months of transplant
(n=60) were analyzed separately for engraftment delay. These patients also achieved
neutrophil engraftment by day 17 and had platelet recovery at a median of 17 days with no
difference compared to the −R patients (p=0.23) (data not shown).
Non-relapse mortality / causes of death—The cumulative incidence of non-relapse
mortality (NRM) at 1, 3, or 5 years did not differ significantly between the two groups (p =
0.06, Figure 2). In multivariate analysis, higher age (≥ 55 years; RR=1.79, p<0.001) and
transplant >1 year from diagnosis (RR=1.68, p=0.002) were associated with higher risk of
NRM. Pre-transplant rituximab did not impact NRM (p=0.18) (Table 2). Causes of death
were similar between the +R and −R groups, with 58–60% of deaths from lymphoma and
40–42% of deaths from causes other than relapse (Table 5).
Relapse/Progression & Progression Free Survival—The risk of relapse/progression
was lower in the +R group compared to the −R group (RR=0.67, p=0.004). Other significant
covariates associated with higher risk of relapse/progression were older age (≥55 years,
RR=1.36, p=0.002), the lack of a complete remission or chemosensitive status at transplant
(p<0.001) and 3 or more lines of prior chemotherapy (RR=1.71, p<0.001).
Progression-free survival was superior in the +R group compared to the −R group resulting
in a lower risk of treatment failure from relapse/progression or death in the +R cohort
compared to the −R cohort (RR= 0.64, p<0.001) (Table 3 & Figure 3). Point-wise estimates
of PFS at the 1 and 3 year time points for the +R cohort vs. the −R cohort were 62% vs.
49% (p=0.002) and 50% vs. 38% (p=0.008) respectively. Other significant covariates
associated with improved progression-free survival and lower risk of treatment failure were
age <55, first complete remission at the time of AuHCT and less than three lines of
preceding chemotherapy (Table 3).
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Survival—Survival was superior in the +R group with a lower relative risk of mortality
(RR= 0.74, p=0.039) (Table 4 & Figure 4). Point-wise estimates of OS at the 1 and 3 year
time points for the +R cohort vs. the −R cohort were 68% vs. 60% (p=0.049) and 57% vs.
45% (p=0.006) respectively. In multivariate analysis, age <55, first complete remission at
the time of AuHCT, less than 3 lines of chemotherapy and later year of transplant were all
associated with lower mortality and improved survival (Table 4).
Timing of Rituximab—The average interval from last rituximab dose to transplant was 5
months. On further analysis, no significant differences in PFS (Figure 5A) or OS (Figure
5B) were seen in patients who received rituximab within 6 months of transplant versus > 6
months prior to transplant.
DISCUSSION
The Parma trial remains the only published prospective, randomized trial comparing salvage
chemotherapy alone to autologous hematopoietic stem cell transplantation (AuHCT) for
relapsed DLBCL. Based on this study, AuHCT remains the standard of care for patients
with chemosensitive relapsed and refractory DLBCL.(6) The Parma trial predates the
introduction of rituximab into clinical practice; in contrast, patients with DLBCL are now
routinely treated with rituximab as part of their frontline and/or subsequent therapies. As a
result, the outcomes following AuHCT for DLBCL in the rituximab era are not fully known.
Our results indicate that pre-transplant rituximab is not associated with impaired
engraftment or increased non-relapse mortality. In addition, improved progression-free and
overall survival was seen in patients exposed to rituximab prior to transplant.
There are several possible explanations for the observation of enhanced PFS and OS
following AuHCT in the rituximab exposed patients. (1) It is possible that the +R group was
a more favorable group based on baseline patient characteristics. However, this seems
unlikely since the +R group was actually older. In addition, the two groups were very similar
in terms of IPI score at transplant, disease status at transplant, performance status, stage,
chemosensitivity and bulky disease. (2) The fact that the +R patients underwent transplant in
later years than the −R group could also account for improved outcomes in the +R group.
However this would only be expected to influence survival by decreasing NRM (due to
improvements in supportive care over time) and would not be expected to affect PFS (since
the conditioning regimens used in both groups were similar). There was no significant
difference in NRM between the two groups. (3) In theory, improved PFS and OS in the +R
group could be due to delayed activity of rituximab that was received during salvage
therapy. However, the average interval from last rituximab dose to transplant was 5 months,
and no significant differences were seen in 1-, 3-, or 5- year PFS or OS in patients who
received rituximab within 6 months of transplant versus > 6 months prior to transplant. (4) It
is possible that pre-transplant rituximab sensitizes or alters specific effector cell populations,
or affects immune reconstitution in ways that lead to enhanced anti-lymphoma effects.
Unfortunately, post-transplant immune reconstitution data was not uniformly collected from
the patients in this study, precluding further testing this hypothesis. (5) Lastly, it is known
that inclusion of rituximab in first-line therapy has improved the outcome of specific subsets
of DLBCL, such as those which are bcl6-negative, bcl2-positive, or of non-germinal center
origin.(10–12) As a result, there could be important biological differences in the +R and −R
patients in our study, which may account for the improved outcome of the +R patients
following AuHCT.
Although several cases of delayed neutropenia associated with rituximab have been
described,(13,14) the stem cell yield following rituximab therapy appears unaffected.(7,15)
An additional concern is that pre-transplant rituximab may affect engraftment kinetics.(7)
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Our study supports the concept that pre-transplant exposure to rituximab does not
compromise peripheral blood stem cell product quality or engraftment.
One might expect a priori that relapsed or refractory DLBCL patients already exposed to
rituximab will be more likely to have rituximab-refractory disease, and will therefore also be
inherently more difficult to rescue with rituximab-containing salvage therapy followed by
AuHCT. However, our data appear to contradict this notion, since patients previously
exposed to rituximab actually had improved PFS and OS.
It is possible that, depending on the exact timing of exposure to rituximab (as part of first-
line therapy and/or with salvage therapy), the outcomes following AuHCT may differ. The
number of patients in the +R group was not sufficient to allow for meaningful subgroup
analysis based on rituximab exposure during first-line therapy or salvage therapy, so our
study does not shed light on this issue. In a recently published study from the GITIL
(Gruppo Italiano Terapie Innnovative nei Linfomi), the benefit of rituximab prior to AuHCT
was most apparent in follicular and diffuse large B-cell lymphoma patients who received
rituximab with salvage therapy but not with first-line therapy.(16) In a much smaller study
from Germany, an improved outcome after AuHCT for aggressive NHL was associated with
addition of rituximab to salvage therapy. In that study, patients were largely (87%)
rituximab-naïve prior to salvage therapy.(17) A recent abstract by Ashraf et al reported
single-center outcomes of 63 DLBCL patients who underwent AuHCT between 1991 and
2008. Similar to our findings, significantly better disease control after AuHCT was seen in
patients who had rituximab as part of their front-line therapy.(18) In the ongoing CORAL
(Collaborative Trial in Relapsed Aggressive Lymphoma) study, relapsed and refractory
CD20-positive DLBCL patients are randomized between 2 different rituximab based salvage
chemotherapy regimens, followed by AuHCT and further second randomization of
observation versus maintenance rituximab.(19) The CORAL study enrolls both patients with
and without rituximab in first-line therapy and upon completion will hopefully further
clarify the impact of rituximab exposure at different time points prior to transplant.
The patient cohorts in this study are representative of a period of transition in practice when
the use of rituximab was increasingly being adopted for DLBCL. Therefore a contemporary
cohort of patients who were rituximab naïve at AuHCT was available for comparison to the
+R cohort. In the context of current clinical practice in the United States, rituximab is
generally used in both first line and subsequent therapies for DLBCL. Thus it is very
unlikely that current AuHCT recipients for DLBCL will be rituximab naive. However, our
study provides post hoc validation for this practice and confirms the safety of prior
rituximab in the AuHCT setting.
In this study, with a median of 42 months of follow up in the +R group, there were only a
small number of patients with 5 or more years of follow up. It was therefore not possible to
perform statistically significant analyses of longer term survival outcomes beyond those
reported above. The magnitude of benefit of pre-transplant rituximab beyond 5 years after
AuHCT remains uncertain. Longer follow up would clarify whether rituximab only serves to
delay DLBCL relapse, or whether it leads to a higher rate of long-term disease-free survival.
The question of whether post-AuHCT “maintenance” therapy (using rituximab and/or other
agents) may offer benefit for DLBCL patients also remains unanswered. Long-term data
from randomized trials, such as the ongoing CORAL study, will be required to further
address these questions.
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Cumulative incidence of neutrophil and platelet recovery after autologous HCT for diffuse
large B-cell lymphoma analyzed by whether rituximab was given prior to transplant.
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Cumulative incidence of NRM after autologous HCT for diffuse large B-cell lymphoma
analyzed by whether rituximab was given prior to transplant.
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Probability of PFS after autologous HCT for diffuse large B-cell lymphoma analyzed by
whether rituximab was given prior to transplant.
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Probability of OS after autologous HCT for diffuse large B-cell lymphoma analyzed by
whether rituximab was given prior to transplant.
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Figure 5A Probability of PFS after autologous HCT for diffuse large B-cell lymphoma
analyzed by whether rituximab was given < 6 months or ≥ 6 months prior to transplant.
Figure 5B Probability of OS after autologous HCT for diffuse large B-cell lymphoma
analyzed by whether rituximab was given < 6 months or ≥ 6 months prior to transplant.
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Table 2






    No rituximab 812 1.00
    Rituximab 174 0.70 (0.41 – 1.18) 0.18
Other significant covariates:
Age at transplant, years
    <55 562 1.00
    ≥ 55 424 1.79 (1.31 – 2.45) <0.001
Time from diagnosis to transplant, years
    ≤1 435 1.00
    >1 551 1.68 (1.21 – 2.34) 0.002
Year of transplant
    1996–1999 728 1.00
    2000–2003 258 0.63 (0.40 – 1.00) 0.05
Abbreviations: CI = confidence interval.
*
Cox models stratified on Karnofsky performance score
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Table 3








    No rituximab 812 1.00
    Rituximab 174 0.64 (0.50 – 0.81) <0.001
Other significant covariates:
Age at transplant, years
    <55 562 1.00
    ≥ 55 424 1.45 (1.23 – 1.71) <0.001
Disease status at transplant
    (1) CR1 167 1.00 <0.001a
    (2) PIF-sensitive 182 1.24 (0.91 – 1.69) 0.18
    (3) PIF-resistant 54 3.38 (2.30 – 4.96) <0.001
    (4) REL-sensitive 298 2.02 (1.53 – 2.67) <0.001
    (5) REL-resistant 69 2.65 (1.83 – 3.82) <0.001
    (6) CR2+ 158 1.57 (1.14 – 2.14) 0.010
    (7) Unknown 58 2.13 (1.45 – 3.15) 0.001
Number of lines of chemotherapy
    ≤2 561 1.00 <0.001b
    >2 418 1.61 (1.36 – 1.91) <0.001
Abbreviations: CI = confidence interval.
*
Cox models stratified on karnofsky performance score
a
Six degrees of freedom
b
Two degrees of freedom
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Table 4






    No rituximab 818 1.00
    Rituximab 176 0.74 (0.56 – 0.99) 0.039
Other significant covariates:
Age at transplant, years
    <55 568 1.00
    ≥ 55 426 1.53 (1.29 – 1.83) <0.001
Disease status at transplant
    (1) CR1 168 1.00 <0.001a
    (2) PIF-sensitive 184 1.29 (0.91 – 1.82) 0.15
    (3) PIF-resistant 54 3.23 (2.14 – 4.87) <0.001
    (4) REL-sensitive 301 2.06 (1.51 – 2.81) <0.001
    (5) REL-resistant 69 2.57 (1.73 – 3.83) <0.001
    (6) CR2+ 159 1.58 (1.12 – 2.24) 0.010
    (7) Unknown 59 2.27 (1.50 – 3.44) <0.001
Number of lines of chemotherapy
    ≤2 564 1.00 <0.001b
    >2 422 1.53 (1.28 – 1.82) <0.001
Year of transplant
    1996–1999 735 1.00
    2000–2003 259 0.73 (0.57 – 0.94) 0.013
Abbreviations: CI = confidence interval.
*
Cox models stratified on karnofsky performance score
a
Six degrees of freedom
b
Two degrees of freedom













Fenske et al. Page 22
Table 5
Causes of death before day 100
Rituximab No Rituximab
Causes of death N eval N (%) N eval N (%)
Number of patients 24 114
  Relapse / progression 14 (58) 68 (60)
  Other causes 10 (42) 46 (40)
      Pulmonary syndrome 2 ( 8) 10 ( 9)
      Infection 2 ( 8) 11 ( 9)
      Organ failure 3 (14) 19 (17)
      Hemorrhage 1 ( 4) 4 ( 3)
      New malignancy 1 ( 4) 1 ( 1)
      Unknown 1 ( 4) 1 ( 1)
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